Novartis Presents Two-Year Data of Cosentyx in P-III JUNIPERA Study for JPsA and ERA at EULAR 2021

 Novartis Presents Two-Year Data of Cosentyx in P-III JUNIPERA Study for JPsA and ERA at EULAR 2021

Novartis Presents Two-Year Data of Cosentyx in P-III JUNIPERA Study for JPsA and ERA at EULAR 2021

Shots:

  • The P-III JUNIPERA study assesses the efficacy and safety of secukinumab (75 /150 mg) vs PBO in 86 children and adolescents aged 2-17yrs. with a confirmed diagnosis of JPsA or ERA (subtype of JIA)
  • The study met its 1EPs i.e delayed time to flare and demonstrates efficacy with more patients achieving and maintains the JIA ACR 30 and JIA ACR 70 responses @12 to 104 wks., favorable safety profile with no new safety signals were identified with 2yrs. treatment
  • The regulatory submissions in the EU and the US are expected in the coming wks. The therapy has received EU and US approval as a 1L systemic treatment for pediatric psoriasis

Click here to­ read full press release/ article | Ref: Novartis | Image: Reuters

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post